POST Online Media Lite Edition



 

Moderna to start local production of COVID-19 mRNA vaccine in Canada

Christian Fernsby |
Moderna, Inc. announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine.

Article continues below




The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses.

Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state-of-the-art manufacturing facility with the collaboration of the Canadian government.

The collaboration aims to provide Canadians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and potential other vaccines, pending licensure.

The facility is intended to also be activated on an urgent basis to support Canada with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model.


What to read next

Glaxo to invest in Germany's CureVac as partner to develop vaccines
Moderna to begin phase-3 coronavirus vaccine trial in July
Moderna to supply 13m doses of COVID-19 vaccine to Philippines